Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy.
We describe a patient with sight threatening thyroid associated ophthalmopathy (TAO) who was successfully treated with infliximab, an anti-tumour necrosis factor (TNF)-a antibody.
Full text links
We have located links that may give you full text access.
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app